abstract |
The topical application to the ocular surface or adjacent regions of the eye of a preparation containing a therapeutically effective amount of an androgen or androgen analogue or a therapeutically effective amount of TGB-β is disclosed as a method of relieving the chronic and acute manifestation of dry eye signs and symptoms in keratoconjunctivitis sicca (KCS), for example in Sjogren's syndrome. Measurement of the increased tear levels of TGF-β is disclosed as a diagnostic test to monitor the therapeutic effect of topical treatment with androgen or androgen analogues. |